LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Sweet's syndrome in the setting of newly initiated risankizumab therapy for pre-existing psoriasis.

    Ahmed, Fadwa / Masur, Samuel / Ben Khadra, Shaza / Baig, Muhammad

    BMJ case reports

    2022  Volume 15, Issue 2

    Abstract: Sweet's syndrome (acute febrile neutrophilic dermatosis) is a rare disorder of unclear aetiology characterised by painful cutaneous lesions, sometimes accompanied by systemic symptoms. It has been associated with several autoimmune conditions, drugs, ... ...

    Abstract Sweet's syndrome (acute febrile neutrophilic dermatosis) is a rare disorder of unclear aetiology characterised by painful cutaneous lesions, sometimes accompanied by systemic symptoms. It has been associated with several autoimmune conditions, drugs, malignancies and infections, though many cases are idiopathic. We describe a case of Sweet's syndrome in a 49-year-old man with pre-existing psoriasis following recent initiation of risankizumab therapy. There are very few reported cases of Sweet's syndrome in association with psoriasis and no existing reports in association with an IL-23 inhibiting medication. Further investigation of the potentially overlapping immunologic pathways implicated in cutaneous reactions to biologic agents and autoimmune conditions such as psoriasis may yield insights into the pathogenesis of such conditions and guide advancements in the rapidly evolving field of targeted biologic therapies.
    MeSH term(s) Antibodies, Monoclonal ; Autoimmune Diseases ; Humans ; Immunotherapy ; Male ; Middle Aged ; Psoriasis/drug therapy ; Sweet Syndrome/chemically induced ; Sweet Syndrome/drug therapy
    Chemical Substances Antibodies, Monoclonal ; risankizumab (90ZX3Q3FR7)
    Language English
    Publishing date 2022-02-08
    Publishing country England
    Document type Case Reports ; Journal Article
    ISSN 1757-790X
    ISSN (online) 1757-790X
    DOI 10.1136/bcr-2021-246774
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study.

    Gibson, Meghan / Subedi, Shova / Barker, David H / Masur, Samuel / Mallette, Meaghan M / Lingannan, Archana / Recinos Soto, Aldo Alejandro / Esharif, Dyadin / Maxwell, Sarah H / Riaz, Muhammad Safwan / Herzlinger, Michael I / Shalon, Linda B / Cerezo, Carolina S / Kasper, Vania L / Ross, Albert M / Leleiko, Neal S / Shapiro, Jason M

    Journal of pediatric gastroenterology and nutrition

    2023  Volume 77, Issue 2, Page(s) 207–213

    Abstract: Objectives: Infliximab (IFX) is commonly used to treat children with inflammatory bowel disease (IBD). We previously reported that patients with extensive disease started on IFX at a dose of 10 mg/kg had greater treatment durability at year one. The aim ...

    Abstract Objectives: Infliximab (IFX) is commonly used to treat children with inflammatory bowel disease (IBD). We previously reported that patients with extensive disease started on IFX at a dose of 10 mg/kg had greater treatment durability at year one. The aim of this follow-up study is to assess the long-term safety and durability of this dosing strategy in pediatric IBD.
    Methods: We performed a retrospective single-center study of pediatric IBD patients started on IFX over a 10-year period.
    Results: Two hundred ninety-one patients were included (mean age = 12.61, 38% female) with a follow-up range of 0.1-9.7 years from IFX induction. One hundred fifty-five (53%) were started at a dose of 10 mg/kg. Only 35 patients (12%) discontinued IFX. The median duration of treatment was 2.9 years. Patients with ulcerative colitis ( P ≤ 0.01) and patients with extensive disease ( P = 0.01) had lower durability, despite a higher starting dose of IFX ( P = 0.03). Adverse events (AEs) were observed to occur at a rate of 234 per 1000 patient-years. Patients with a higher serum IFX trough level (≥20 µg/mL) had a higher rate of AEs ( P = 0.01). Use of combination therapy had no impact on risk of AEs ( P = 0.78).
    Conclusions: We observed an excellent IFX treatment durability, with only 12% of patients discontinuing therapy over the observed timeframe. The overall rate of AEs was low, the majority being infusion reactions and dermatologic conditions. Higher IFX dose and serum trough level> 20 µg/mL were associated with higher risk of AEs, the majority being mild and not resulting in cessation of therapy.
    MeSH term(s) Humans ; Child ; Female ; Infant ; Child, Preschool ; Male ; Infliximab/adverse effects ; Retrospective Studies ; Follow-Up Studies ; Gastrointestinal Agents/adverse effects ; Inflammatory Bowel Diseases/drug therapy ; Colitis, Ulcerative/drug therapy ; Treatment Outcome
    Chemical Substances Infliximab (B72HH48FLU) ; Gastrointestinal Agents
    Language English
    Publishing date 2023-04-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603201-1
    ISSN 1536-4801 ; 0277-2116
    ISSN (online) 1536-4801
    ISSN 0277-2116
    DOI 10.1097/MPG.0000000000003794
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1728: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Histological features of ileitis differentiating pediatric Crohn disease from ulcerative colitis with backwash ileitis.

    Sahn, Benjamin / De Matos, Vera / Stein, Ronen / Ruchelli, Eduardo / Masur, Samuel / Klink, Andrew J / Baldassano, Robert N / Piccoli, David A / Russo, Pierre / Mamula, Petar

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    2017  Volume 50, Issue 2, Page(s) 147–153

    Abstract: Background/aim: Pediatric ileocolonic Crohn disease (CD) may be difficult to distinguish from ulcerative colitis (UC) with backwash ileitis (BWI). The primary aim of the study was to determine the probability of CD in children with a confluent colitis ... ...

    Abstract Background/aim: Pediatric ileocolonic Crohn disease (CD) may be difficult to distinguish from ulcerative colitis (UC) with backwash ileitis (BWI). The primary aim of the study was to determine the probability of CD in children with a confluent colitis and ileitis when newly diagnosed with inflammatory bowel disease (IBD).
    Methods: A retrospective observational study of 100 newly diagnosed patients with IBD was performed. Two pathologists reviewed ileal biopsy specimens for 8 histological features. Biopsy and clinical features were evaluated for predictive ability of a final diagnosis of CD.
    Results: The presence of crypt distortion, lamina propria (LP) expansion, and acute LP inflammation combined with 4 clinical variables in multivariate regression analysis had adequate discriminative validity when comparing the mean probability of a final CD diagnosis between CD and not-CD groups (0.90 vs. 0.59, p value <0.001). When crypt distortion, LP expansion, and acute LP inflammation are present in any combination, the sensitivity and specificity for presence of CD ranges 38.4-57% and 92.9-100%, respectively.
    Conclusions: Combining histological features of ileitis and clinical variables can adequately discriminate between the presence and absence of Crohn disease in children who present with confluent colitis and ileitis. Combined presence of certain histological features has high specificity for CD.
    MeSH term(s) Adolescent ; Child ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/pathology ; Colon/pathology ; Crohn Disease/diagnosis ; Crohn Disease/pathology ; Diagnosis, Differential ; Female ; Humans ; Ileitis/diagnosis ; Ileitis/pathology ; Ileum/pathology ; Logistic Models ; Male ; Multivariate Analysis ; ROC Curve ; Retrospective Studies
    Language English
    Publishing date 2017-10-19
    Publishing country Netherlands
    Document type Journal Article ; Observational Study
    ZDB-ID 1459373-7
    ISSN 1878-3562 ; 1125-8055
    ISSN (online) 1878-3562
    ISSN 1125-8055
    DOI 10.1016/j.dld.2017.10.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1134: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells.

    Hepworth, Matthew R / Fung, Thomas C / Masur, Samuel H / Kelsen, Judith R / McConnell, Fiona M / Dubrot, Juan / Withers, David R / Hugues, Stephanie / Farrar, Michael A / Reith, Walter / Eberl, Gérard / Baldassano, Robert N / Laufer, Terri M / Elson, Charles O / Sonnenberg, Gregory F

    Science (New York, N.Y.)

    2015  Volume 348, Issue 6238, Page(s) 1031–1035

    Abstract: Inflammatory CD4(+) T cell responses to self or commensal bacteria underlie the pathogenesis of autoimmunity and inflammatory bowel disease (IBD), respectively. Although selection of self-specific T cells in the thymus limits responses to mammalian ... ...

    Abstract Inflammatory CD4(+) T cell responses to self or commensal bacteria underlie the pathogenesis of autoimmunity and inflammatory bowel disease (IBD), respectively. Although selection of self-specific T cells in the thymus limits responses to mammalian tissue antigens, the mechanisms that control selection of commensal bacteria-specific T cells remain poorly understood. Here, we demonstrate that group 3 innate lymphoid cell (ILC3)-intrinsic expression of major histocompatibility complex class II (MHCII) is regulated similarly to thymic epithelial cells and that MHCII(+) ILC3s directly induce cell death of activated commensal bacteria-specific T cells. Further, MHCII on colonic ILC3s was reduced in pediatric IBD patients. Collectively, these results define a selection pathway for commensal bacteria-specific CD4(+) T cells in the intestine and suggest that this process is dysregulated in human IBD.
    MeSH term(s) Animals ; Apoptosis/immunology ; Autoimmunity ; Bacteria/immunology ; CD4-Positive T-Lymphocytes/immunology ; Colon/microbiology ; Female ; Flagellin/genetics ; Flagellin/immunology ; Histocompatibility Antigens Class II/immunology ; Humans ; Immunity, Innate ; Inflammatory Bowel Diseases/immunology ; Inflammatory Bowel Diseases/microbiology ; Lymphocyte Activation ; Male ; Mice ; Mice, Inbred C57BL ; Symbiosis ; Thymus Gland/immunology
    Chemical Substances CBir1 flagellin ; Histocompatibility Antigens Class II ; Flagellin (12777-81-0)
    Language English
    Publishing date 2015-05-29
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.aaa4812
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 27: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 77: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top